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Abstract
Introduction: The aim of this study was to determine whether mycophenolate mofetil (MMF) pharmacokinetics
(PK) under combined MMF and prednisone remission-maintenance therapy can predict systemic lupus
erythematosus (SLE) clinical flares.
Methods: At inclusion, steady-state PK parameters of the MMF active form, mycophenolic acid (MPA), and its
glucuronide metabolite (MPAG) were determined for 25 stable SLE patients without renal manifestations. Disease
activity was assessed during 6 months of follow-up. Potential relationships between those entry MMF-PK variables
and clinical outcome were analyzed.
Results: MMF controlled disease activity in 17 patients (successes) and failed to do so for 8 others (failures). For
failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours
(AUC0-12 h) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C12 h) (medians:
1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C12 h ratios (medians: 18.7 vs 10.2,
P = 0.02) were significantly higher. According to our receiver operating characteristics curve analysis, MPA C12 h
was best able to discriminate a flare during follow-up (93% sensitivity, 85% specificity). A 3-mg/L cut-off had 92%
negative-predictive value for developing a flare during follow-up.
Conclusions: For our SLE patients without renal manifestations, clinical flares developing under maintenance
therapy were associated with steady-state inclusion MPA C12 h < 3 mg/L.
Introduction
Systemic lupus erythematosus (SLE) is a chronic remit-
ting-and-relapsing disease that engenders considerable
health-care costs for each patient and may require long-
term treatment with immunosuppressive agents [1].
Mycophenolate mofetil (MMF), an immunosuppressant
widely used to prevent solid organ transplant rejection
[2], is being used increasingly to induce SLE remission
of minor relapses and to maintain remission after
induction therapy [1]. No recommendations for optimal
MMF dose are available for these patients. The dose
used to control SLE activity usually ranges from 1.5 to
3 g daily and is based largely on clinical experience,
which is very limited. However, most patients experi-
ence periodic disease flares, so maintaining disease con-
trol remains a challenge. The lupus flare rate varies
among studies, often because of the different popula-
tions studied [1].
In the transplant setting, the observed association
between drug exposure and the risk of acute rejection
has encouraged the routine determination of areas
under the time-concentration curve between 0 and 12
hours (AUC0-12 h)o fm y c o p h e n o l i ca c i d( M P A ) ,t h e
MMF active form [2]. MPA monitoring after MMF
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patient outcomes over currently recommended fixed-
dose strategy [3], although controversy persists [4]. Con-
versely, for patients with SLE, very few data are available
on MMF pharmacokinetic-pharmacodynamic (PK-PD)
relationships: an association between disease activity and
plasma MPA levels was recently demonstrated in
patients with autoimmune diseases [5], as was a concen-
tration-effect relationship between MPA exposure and
SLE immunological activity [6].
In light of those findings, we postulated that inade-
quate immunosuppressive maintenance therapy for SLE
reflected insufficient exposure to MPA. This study was
conducted to evaluate whether initial steady-state MMF
PK parameters in SLE patients without renal manifesta-
tions in remission could be predictive of clinical flares.
Therefore, we determined those PK parameters for
MPA and its main glucuronide metabolite (mycopheno-
lic acid glucuronide, or MPAG) in SLE patients and
then examined the parameters’ respective predictive
values for flares over the next 6 months.
Materials and methods
Patients
This single-center, observational study evaluated PK-PD
relationships for unselected SLE patients with only
extrarenal manifestations, which were defined according
to the American College of Rheumatology. Patients were
routinely followed between September 2005 and January
2008 in our hospital’s internal medicine department.
Patients gave written informed consent before being
included. The study was approved by our local ethics
committee (CHU de Bordeaux).
At the time of inclusion, all patients had completed
induction therapy and were on a maintenance regimen
comprised exclusively of MMF and low-dose predni-
sone. The main indications for starting MMF were
remission maintenance after induction therapy with
pulsed cyclophosphamide or treatment of minor disease
relapses of hematological, cutaneous, articular, pulmon-
ary, and/or cardiac SLE manifestations. Five patients
who suffered minor relapses had received first-line ther-
apy with hydroxychloroquine or azathioprine and were
switched to MMF before inclusion.
Patients who had active renal involvement (protei-
nuria of greater than 0.5 g/24 hours with urinary casts
or hematuria or both), renal impairment (glomerular
filtration rate (GFR) calculated according to the Cock-
croft-Gault formula of less than 60 mL/minute per
1.73 m
2), and/or hepatic dysfunction were not included,
nor were patients who had used cyclosporine, cholestyr-
amine, magnesium- or aluminium-containing antacid,
rifampicin, and/or antiviral within the 30 days preceding
study entry.
Inclusion steady-state PK parameters were determined
for all patients who demonstrated SLE regression or sta-
bilization for at least 1 month. Included patients were
those who had been taking a stable MMF dose (1 to
3 g/day) for at least 1 month with either declining oral
prednisone (0.25 to 0.5 mg/kg per day) or prednisone
maintenance (5 to 10 mg/day) therapy. MMF dose adap-
tations were initially made on the basis of tolerance and
clinical response, and the inclusion MMF dose was
maintained throughout follow-up. To avoid a potential
influence of prednisone doses on clinical outcome, a
standard predefined tapering regimen was applied to all
patients: the prednisone dose had been stable for at
least 15 days for all patients before inclusion and was
maintained for 2 weeks thereafter and then tapered
throughout follow-up (5 mg every 15 days with the
objective of withdrawing prednisone for patients receiv-
ing 0.25 to 0.5 mg/kg per day or 1 mg every 15 days for
patients under maintenance doses until discontinuation).
Patients who discontinued MMF because of intolerance
or non-compliance or both were excluded from the final
PK-PD analysis.
Pharmacokinetic analysis
For each patient, nine blood samples were collected in
ethylenediaminetetraacetic acid-containing tubes before
and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after MMF admin-
istration. Plasma MPA and MPAG concentrations were
determined with chromatographic assays coupled with
mass spectrometry [7]. A non-compartmental model
with extravascular input for plasma data was used to
estimate maximum MPA and MPAG concentrations
(Cmax), times to maximum concentration (Tmax),
12-hour trough concentrations (C12 h), and AUC0-12 h,
which was estimated with the logarithmic trapezoidal
rule, and their MPAG/MPA AUC0-12 h and C12 h ratios
were calculated.
Follow-up and clinical outcomes
The primary outcome measure was the occurrence of
clinical flares during the 6 months following entry PK
determinations. At each subsequent monthly visit, all
patients underwent a complete physical examination
and laboratory testing. Serum albumin, aspartate amino-
transferase, alanine aminotransferase, and g-glutamyl-
transferase concentrations and GFR were determined,
and corticosteroid dose was recorded. Biological analyses
were also performed: complete blood cell count, urinaly-
sis, C3 and C4 assays, antinuclear antibody test, and
anti-double-stranded DNA.
Clinical outcome was assessed with the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI)
score. A flare was defined as an increase in SLEDAI
score of at least 3 points since the previous examination
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cally stable or regressed (SLEDAI score stabilization or
improvement) during follow-up were classified as suc-
cesses, whereas outcomes of patients whose disease was
not controlled by the maintenance regimen and who
experienced a flare were considered failures.
Statistical analyses
Patient characteristics and PK data are expressed as
median and interquartile range (IQR). Mann-Whitney U
test or Fisher exact test (univariate analysis) was used to
assess the relationship between each demographic, bio-
logical, or PK parameter and clinical outcome. Correla-
tions were established with the Spearman correlation
test. Data were analyzed with Statistica software (version
6.1; StatSoft, Créteil, France). Receiver operating charac-
teristic (ROC) curves were analyzed to determine which
parameters could best discriminate a clinical flare. Areas
under the ROC curves (AUC ROCs) and their 95% con-
fidence intervals (CIs) were calculated using the method
of Hanley and McNeil. AUC ROCs of potentially predic-
tive parameters were compared using Analyse-it soft-
ware (Analyse-it Software, Ltd., Leeds, UK). The
threshold value providing the best trade-off between
sensitivity and specificity would be recommended as the
discriminant cutoff. A P value of less than 0.05 defined
statistical significance.
Results
Patient characteristics
The demographic and disease characteristics and inclu-
sion PK parameters of the 26 Caucasian SLE patients
without extrarenal manifestations are shown in Table 1.
As indicated by the SLEDAI scores, SLE was clinically
stable or had regressed for at least 1 month at entry,
and all patients met PK steady-state conditions. Twenty-
one patients ingested 2 g/day of MMF; daily intake was
1 or 3 g for 2 patients each, and 1 patient took 1.5 g/
day. Co-medications were oral prednisone (range of 5 to
45 mg/day), calcitriol, and proton-pump inhibitors for
all patients. The median MPA AUC0-12 h was 64.7 mg/
hour per L, with high between-patient variability, as
attested by a coefficient of variation (CV) of 44%.
No significant correlations were observed between
MPA AUC0-12 h and serum albumin (r = -0.14, P =0 . 2 )
or body weight (r =0 . 2 2 ,P = 0.3). Plasma MPAG was a
mean of 15-fold higher than MPA (median MPAG
AUC0-12 h of 775.3 mg/hour per L), with wide between-
subject variability of glucuronidation (CV = 43%). The
MPAG/MPA AUC0-12 h and MPAG/MPA C12 h ratios
were highly correlated (r = 0.60, P = 0.005). A positive
correlation was observed between MMF dose and MPA
AUC0-12 h (r =0 . 5 8 ,P =0 . 0 1 )o rM P AC 12 h (r =0 . 5 3 ,
P = 0.02). No significant correlation could be established
between the C12 h ratios and serum albumin (r = 0.22,
P =0 . 3 ) ,G F R( r = 0.10, P = 0.70), or prednisone dose
(r = -0.16, P = 0.2). Lower C4 concentrations tended to
be correlated with lower MPA C12 h (r = 0.44, P = 0.08).
Relationships between the entry steady-state
pharmacokinetic parameters and clinical outcomes
During follow-up, SLE remained stable or regressed in
17 patients and relapsed in 8. The median MMF dura-
tion before the flare was 5 (IQR of 4 to 6) months. The
specific SLE manifestations were new arthritis and active
glomerulonephritis in 3 patients, arthritis or myositis or
both in 2, and vasculitis or cardiorespiratory and neuro-
logical symptoms in 1 patient, and cytopenia and myosi-
tis in 1 patient. One patient had MMF side effects
(diarrhea, nausea, and abdominal pain) requiring its dis-
continuation and thus was excluded from the PK-PD
analysis. The others tolerated it well.
The PK parameters were compared between the 17
successes and 8 failures (Table 1). Patients whose SLE
remained clinically stable or regressed during the 6
months of follow-up had baseline MPA AUC0-12 h and
MPA C12 h that were significantly higher than those of
patients whose disease flared. The latter had significantly
higher MPAG/MPA C12 h ratios (Figure 1a-c) and
significantly lower MPAG Tmax. Successes and failures
had comparable median inclusion prednisone doses
(Table 1). Prednisone doses did not differ statistically
between successes and failures at endpoint (respective
medians of 5 (IQR of 5 to 5) mg versus 5.5 (IQR of 5.5
to 7.5) mg; P = 0.60).
Receiver operating characteristic curve analysis
AUC ROCs were 0.86 (95% CI 0.71 to 1), 0.89 (95% CI
0.75 to 0.98), and 0.75 (95% CI 0.56 to 0.90), respec-
tively, for MPA AUC0-12 h,M P AC 12 h,a n dM P A G /
MPA C12 h ratio. Comparison of AUC ROCs showed no
significant difference between MPA C12 h and AUC0-12 h
(P = 0.77). MPA AUC0-12 h and C12 h were strongly cor-
related (r =7 0 ,P < 0.05), but the latter appeared to be
better able to discriminate a clinical flare during follow-
up, with 93% sensitivity and 85% specificity (Figure 2). A
threshold of 3 mg/L had 92% negative predictive value
for developing a flare during follow-up.
Discussion
Although the majority of our patients received the stan-
dard MMF dose of 2 g/day, broad interpatient CVs for
its PK parameters were observed. Moreover, 31% of our
patients relapsed during the 6-month follow-up while
on this recommended dose. Considering the attention
focused on individualizing MMF therapy for transplan-
tees [3], we postulated that SLE flares occurring under
maintenance therapy reflected insufficient exposure to
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the possible relationships between MMF PK parameters
and SLE activity under maintenance therapy.
Significantly lower MPA AUC0-12 h and C12 h and
higher MPAG/MPA C12 h ratios were observed at inclu-
sion for patients deemed therapeutic failures during fol-
low-up. Thus, SLE flares were associated with lower
plasma MPA concentrations. Our univariate analyses
did not find C3 and C4 levels or anti-double-stranded
DNA antibody positivity to be predictive of such exacer-
bations. It is commonly accepted that SLE patients may
suffer clinical flares without serological changes [9], but
in our study, this circumstance could be explained by
our small sample size. The only studied parameter dif-
fering significantly between clinical successes and fail-
ures was entry steady-state MPA exposure.
T h eR O Cc u r v ea n a l y s i ss h o w e dM P AC 12 h to be as
effective a marker as AUC0-12 h to discriminate a clinical
flare during follow-up. That observation contradicts
findings in the transplantation setting, in which a poor
correlation between MPA C12 h and AUC0-12 h was
described [2], making the latter the marker of choice to
prevent acute rejection.
According to our results, therapeutic drug monitoring
based on the simple measurement of MPA C12 h enabled
the prediction of SLE patients’ clinical outcomes.
Table 1 Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical
outcome (univariate analysis)
Inclusion characteristic Total
n =2 6
Successes
n =1 7
Failures
n =8
P value
a
Demographic
Females/Males, number 16/10 12/5 4/4 0.28
b
Age, years 46 (35-61)
a 46.5 (35-61) 46 (38-61) 0.9
Body weight, kg 60 (56-75) 60 (56-75) 62 (58-82.5) 0.62
Disease
Duration before entry, months 11 (7-14) 11 (7-12) 10 (6-13) 0.30
SLEDAI score 0 (0-2) 0 (0-2) 0 (0-2) 0.20
C3, g/L 1 (0.6-1.1) 1 (0.9-1.1) 0.8 (0.56-0.96) 0.21
C4, g/L 0.2 (0.1-0.2) 0.2 (0.1-0.2) 0.2 (0.16-0.24) 0.78
Anti-double-stranded DNA, IU/mL 24 (6-51) 8 (1 -32) 38 (9 -55) 0.19
Biological
GFR, mL/minute 95 (67-125) 95 (67-125) 93.5 (76-109) 0.64
Albumin, g/L 40 (39.8-43.8) 40 (37.9-43.8) 42.8 (40-46.9) 0.33
Aspartate aminotransferase, IU/L 23 (19-26) 23 (17.5-24.5) 28 (20-33) 0.26
Alanine aminotransferase, IU/L 22 (15-29) 19 (13-24.5) 25 (19-37) 0.21
g-Glutamyltransferase, IU/L 24 (17-63) 23 (17-21) 42 (17-61) 0.92
Treatment
MMF, g/day 2 (2-2) 2 (2-2) 2 (2-2) 0.9
Corticosteroids, mg/day 11 (7-35) 10 (5-20) 15 (7-45) 0.37
Months of MMF therapy 2 (1-3) 2 (1-3) 2 (1-3) 0.56
Months of corticosteroids 10 (6-13) 10 (5-15) 9 (5-14) 0.12
MPA pharmacokinetic parameters
AUC0-12 h, mg/hour per L 64.7 (38.2-82) 73.1 (61.8-95) 37.7 (32-43.7) 0.003
Cmax, mg/L 16.1 (9.5-18.5) 16.3 (9.7-17.4) 13.3 (7-22.5) 0.69
Tmax, hours 1 (1-2) 1 (1-2) 1.1 (1-2) 0.82
C12 h, mg/L 2.4 (1.5-4.1) 3.7 (2.3-4.9) 1.5 (0.6-2.1) 0.008
MPAG pharmacokinetic parameters
AUC0-12 h, mg/hour per L 775.3 (475-1,026) 791 (635-1,166) 678.8 (426-840.6) 0.22
Tmax, hours 2 (2-3) 2.3 (2-3) 1.3 (1-2) 0.01
C12 h, mg/L 32.1 (24.3-41.9) 34.7 (26.4-49.2) 29.8 (15.5-40) 0.26
MPAG/MPA AUC0-12 h ratio 11.5 (8.3-20.7) 10.9 (6.2-14.8) 18.7 (14.1-22.7) 0.07
MPAG/MPA C12 h ratio 11.5 (6.8-17.3) 10.2 (6.3-15) 18.7 (11.5-47.2) 0.02
Values are expressed as median (interquartile range) unless stated otherwise.
aMann-Whitney U test;
bFisher exact test. AUC0-12 h, area under the plasma
concentration-versus-time curves for hours 0 to 12; C12 h, 12-hour trough concentration; Cmax, maximal concentration; GFR, glomerular filtration rate (estimated
with the Cockcroft-Gault formula); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; SLEDAI, Systemic Lupus
Erythematosus Disease Activity Index; Tmax, time to maximal concentration.
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studies, one conducted on 20 patients with SLE [6] and
the other on 39 patients with SLE or vasculitides [5], and
confirmed the results reported in the latter. First, our
study population was characterized by a mean ± standard
deviation MPA AUC0-12 h of 64 ± 28 mg/hour per L,
which is very close to their value of 66 ± 22 mg/hour per
L[ 5 ] .T h o s ea u t h o r sa l s op r o p o s e daC 12 h threshold of
3 mg/L for MPA monitoring. This threshold provided
the best trade-off between sensitivity and specificity, with
92% negative predictive value in our study.
Unfortunately, our results cannot be compared with
those obtained by others, mainly because our inclusion
criteria were more restricted, as we enrolled only SLE
patients without renal manifestations to ensure clinical
homogeneity of the population. Because of the heteroge-
neous nature of clinical autoimmune disease manifesta-
tions, flares are often evaluated using an activity index.
More than 20 different lupus activity scales have been
used, and the Birmingham vasculitis activity score is
used widely in therapeutic studies on systemic vasculi-
tides. We thought that pooling systemic vasculitis and
SLE patients would prevent a clear general definition of
‘flare’ and thereby introduce bias into the determination
of efficacy thresholds.
We used one of the best characterized and most routi-
nely used SLE scores and defined a flare as an increase
in SLEDAI score of at least 3 points since the previous
visit (1 month earlier). Only severe clinical exacerbations
requiring therapeutic changes were considered whereas
mild and moderate flares were excluded, and this choice
might represent a limitation of our study. Another pos-
sible limitation is that, owing to the small sample, the
relationship between the PK and MMF side effects
could not be examined. However, 70% of our patients
had an AUC0-12 h of greater than 60 mg/hour per L
without any adverse events. Third, patients were evalu-
ated for only 6 months, and according to Posalki and
colleagues [10], although disease activity may regress
during the first year of MMF treatment, this immuno-
suppressant fails to prevent extrarenal flares when con-
tinued beyond 2 years. Thus, it is likely that our flare
rate would have been higher if follow-up had been
longer. Finally, an important limitation is our study’s
lack of statistical power and the participation of only
one center, perhaps explaining why no association was
observed between clinical outcome and variables (age,
sex, or biological markers) other than PK. Consequently,
we were not able to identify confounding variables (for
example, age, weight, steroid doses, or sex) in a multi-
variate analysis [11]. However, for several reasons, we
think that prednisone withdrawal could have had only a
minor impact on clinical response: low prednisone doses
at inclusion (median of 11 mg), the standard tapering
regimen applied to all patients, and comparable median
entry and endpoint prednisone doses for successes and
failures.
Despite these limitations, our results confirmed the
large interpatient CV of the MMF PK parameters for
SLE patients, as previously described for transplant reci-
pients [2], showed that therapeutic drug monitoring
under MMF steady-state conditions in SLE without
renal manifestations predicted the clinical outcome
under maintenance therapy, and demonstrated that such
PK analyses should be based on MPA C12 h,a s
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Figure 1 Box plots at baseline for endpoint successes and
failures. (a) Area under the plasma concentration-versus-time
curves between 0 and 12 hours of mycophenolic acid (MPA AUC0-12
h). (b) Twelve-hour trough concentrations of MPA (MPA C12 h). (c)
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Page 5 of 7previously reported [5]. We concluded that the discrimi-
nant threshold values were highly dependent on the
study population and the disease activity index chosen.
Indeed, our PK results and proposed efficacy threshold
are different from those observed in a cohort that
included a majority of patients with lupus nephritis [12].
This discrepancy is logical given the predominant influ-
ence of renal function on MPAG and plasma MPA
exposure [2].
Therapeutic failures might benefit from optimized
dosing. In our opinion, 31% of our patients should have
been prescribed daily MMF doses higher than the stan-
dard 2 g. Indeed, the impact of higher MMF doses mer-
its further study. One possible explanation for failures
on MMF is the increased clearance suggested by the
higher metabolite levels, as the MPAG/MPA C12 h ratio
was significantly higher in patients who developed flares.
Low serum albumin level, renal dysfunction, and co-
medications (corticosteroids) are the main factors
usually blamed for raising metabolite concentrations [2].
As expected based on our inclusion criteria and sample
size, we did not establish any significant correlation
between MPAG/MPA C12 h and serum albumin, corti-
costeroid dose, or GFR. Conversely, the MPAG Tmax
was significantly lower for patients failing on MMF,
thereby raising a hypothetically increased glucuronida-
tion ability in failures, which favors MPA metabolism
and excretion. Glucuronidation might be under genetic
control, and this needs to be confirmed in future clinical
studies [13].
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For our SLE patients without renal manifestations, the
occurrence of disease flares under MMF and prednisone
maintenance therapy was significantly associated with
lower MPA C12 h. We now recommend a target thresh-
old of 3 mg/L for our patients. Further studies on larger
populations are needed to confirm the ability of MPA
PK parameters to predict clinical outcomes of SLE
patients.
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